INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia

INEAS’s Cost-Effectiveness Analysis of Vemurafenib: Paving the Way for Value-Based Pricing in Tunisia

The Tunisian Health Technology Assessment (HTA) body, INEAS, conducted a cost-effectiveness analysis (CEA) of vemurafenib in the treatment of locally advanced or metastatic BRAF V600-mutated melanoma. The objective of this analysis was to enable the use of value-based pricing as a new approach to pr...

Full description

Saved in:
Bibliographic Details
Main Authors: Mouna Jameleddine, Nabil Harzallah, Hela Grati, Marie Christine Odabachian Jebali, Jaafar Chemli, Sebastián García Martí, Natalie Soto, Andrés Pichon-Riviere, Chokri Hamouda
Format: Article
Language:English
Published: Taylor & Francis Group 2024-10-01
Series:Journal of Market Access & Health Policy
Subjects:
vemurafenib
advanced melanoma
targeted therapy
BRAF V600
cost-effectiveness
cost utility
Online Access:https://www.mdpi.com/2001-6689/12/4/23
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2001-6689/12/4/23

Similar Items